Veloxis Pharmaceuticals A/S Release: Phase 3 Clinical Study Data Demonstrating LCP-Tacro’s Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation
Published: Sep 04, 2013
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis’ once-daily LCP-Tacro™, now with the trade name of Envarsus®, demonstrated comparable efficacy and safety compared to twice-daily tacrolimus (Prograf®).
Help employers find you! Check out all the jobs and post your resume.